Pelin ALBAYRAK, Serap TEBER, Gökçen ÖZ TUNÇER, Muhammed Gültekin KUTLUK, Özben AKINCI GÖKTAŞ

Cutaneous Ulceration Associated with Subcutaneous Interferon Beta 1a Injection

ISSN: 1307-4490
Yayın Aralığı: 6
Başlangıç: 2007
Yayıncı: -

Subcutaneous interferon beta 1a (IFN β 1a) has been shown to reduce relapse rates in patients with relapsing-remitting multiple sclerosis. We report the occurrence of severe necrotizing cutaneous reactions in a 19-year-old girl. She self injected IFN β 1a three times a week on the abdomen and both thighs. Treatment was initially well tolerated, but she described erythematous patches and local pain at the injection sites recently. The areas on the abdomen became violaceous with necrotic ulcers. Her therapy was changed to 0.5 mg fingolimod. The lesions began to improve and cicatrize after several weeks with postinflammatory hyperpigmentation. Early recognition of severe local adverse reactions and correction of the injection technique is important.

Anahtar Kelimeler:

Interferon beta 1a

PDF

___

1. PRISMS (Prevention of Relapses and Disability by Interferon betala Subcutaneously in Multiple sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-la in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-504.
2. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta 1b: The clinical and histologic spectrum. J Am Acad Dermatol 1997;37:5538.
3. Lebrun C, Bertagna M, Cohen M. Cutanous side effects of immunomodulators in MS. Int MS J 2011;17:88-94.
4. Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: An observational study. BMC Neurol 2011;11:144.
5. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995;332:1584.